Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Acquired Immunodeficiency Syndrome: full-pipeline trial registry
1 of 18 indexed Acquired Immunodeficiency Syndrome trials are currently recruiting.
Corpus placement: #953 of 28,707 conditions by registered trial count.
18 US clinical trials · 1 currently recruiting · #953 of 28,707 conditions by registered trial count
Acquired Immunodeficiency Syndrome: 18 US clinical trials tracked, 1 recruiting.
Acquired Immunodeficiency Syndrome is the subject of 18 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Gilead Sciences, running 4 of these trials.
Enrollment posture brief
Registry condition acquired-immunodeficiency-syndrome
OPEN 1 | RECR 6% | LATE 6 | EARLY 7 | RANK #953 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Stage IIA Breast Cancer (6% recruiting · 18 trials)
Acquired Immunodeficiency Syndrome lists 1 open slots (6% of 18 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Acquired Immunodeficiency Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Acquired Immunodeficiency Syndrome is recruiting below its size-band peers.
1 of 18 indexed trials (5.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Acquired Immunodeficiency Syndrome research.
Gilead Sciences accounts for 4 of 18 trials (22.2%). 14 distinct sponsors appear on at least one study for this condition label.
-
Typical Acquired Immunodeficiency Syndrome enrolment sits around 106 participants.
Median target enrolment is 106 among the 18 trials that report a genuine target (sentinel values excluded). 8 of those (44.4%) plan for fewer than 100 participants.
-
Acquired Immunodeficiency Syndrome research is mostly interventional.
15 interventional and 3 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
18 total, page 1 of 1
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
M.D. Anderson Cancer Center
NCT02479698
Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults
Boris Juelg, MD PhD
NCT04983030
HIV Prevention Intervention for Couples
National Development and Research Institutes
NCT00325585
Multidisciplinary Inpatient Palliative Care Intervention
Kaiser Permanente
NCT00325611
Managerial Database II
University of North Carolina, Chapel Hill
NCT01322217
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Gilead Sciences
NCT01475838
Medications for Chronic HIV: Education and Collaboration
Boston University
NCT01038076
Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Gilead Sciences
NCT01440569
HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)
Yale University
NCT03583138
Thalidomide to Treat Oral Lesions in HIV-Infected Patients
National Institute of Dental and Craniofacial Research (NIDCR)
NCT00001524
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Gilead Sciences
NCT01363011
Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
Gilead Sciences
NCT01967940
Twins Study of Gene Therapy for HIV Infection
National Human Genome Research Institute (NHGRI)
NCT00001535
Mesalamine to Reduce T Cell Activation in HIV Infection
University of California, San Francisco
NCT01090102
Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection
National Cancer Institute (NCI)
NCT00001386
Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex Infection
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001763
Efficacy of Elevated CD4 Counts on CMV Retinitis
National Eye Institute (NEI)
NCT00091884
Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001646
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 3 |
| Phase 3 | 5 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Acquired Immunodeficiency Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Acquired Immunodeficiency Syndrome trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Acquired Immunodeficiency Syndrome page
18 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Acquired Immunodeficiency Syndrome trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Gilead Sciences sponsors the most Acquired Immunodeficiency Syndrome trials on record, review their full trial history before evaluating a specific study. See Gilead Sciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acquired Immunodeficiency Syndrome condition card totals 18 registered trials; most-linked intervention COBI; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.